// App-Quantinova.ai

573 : The TRUST Trial: Anti-Drug Antibody Formation In a Patient With Hemophilia With Inhibitors After Receiving The Activated Factor VII Product Bay 86-6150

Researchers

Presenter

  • Johnny N. Mahlangu

Principal Investigators

  • Pei Lin Koh

  • Heng Joo Ng

  • Toshko Lissitchkov

  • Marion Hardtke

  • Jens Schroeder

Medical Centers

  • Department of Medicine, National University Hospital, Singapore, Singapore

  • Department of General Surgery, Singapore General Hospital, Singapore, Singapore

  • Molecular Medicine and Haematology, Hemophilia Comprehensive Care Center, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa

  • NSHAT Haematology, Sofia, Bulgaria

Locations

  • Bulgaria

  • South Africa

  • Singapore

Companies

  • Bayer

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • BAY 86-6150

  • FVIII

  • NiaStase

  • rFVIIa

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved